February 19, 2019 07:27 AM EST
R&D

Dogged by safe­ty is­sues, Eli Lil­ly and Pfiz­er tout their lat­est PhI­II for an­ti-NGF pain drug tanezum­ab

John Carroll

Editor & Founder

Sci­en­tists at Eli Lil­ly and Pfiz­er have racked up a fresh set of pos­i­tive ef­fi­ca­cy num­bers for their close­ly-watched an­ti-NGF pain drug tanezum­ab. But once …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times